Economies of Scale in The Russian Pharmaceutical Industry: Empirical Assessments

Alexander B. Gusev, Maksim A. Yurevich

The Financial University under the Government of the Russian Federation, Moscow, Russia

Abstract

The prolonged sluggish development of the Russian pharmaceutical industry has been attributed to relatively low investment activity in the sector. This, in turn, has led to a high dependency on imported medicines in Russia. The aim of the research was to identify the economic factors contributing to the chronic undercapitalization of the industry. The main suspicion was the absence of economies of scale in a sector that requires high-tech equipment and numerous other material and intellectual resources, which automatically makes launching new productions and significantly expanding existing ones unprofitable. This assumption formed the central hypothesis of the study, which was supplemented by the presumption of the existence of a revenue threshold for enterprises. Comparing actual data with this threshold would make it possible to determine whether an organization experiences negative or positive economies of scale. Given the state licensing of pharmaceutical manufacturing activities, the scope of companies considered was precisely defined. The industry-specific characteristics of license-holding organizations and the availability of performance data from 2004 to 2023 in the SPARK-Interfax system enabled the formation of a final sample of 320 manufacturing enterprises and the methodological determination of the economies of scale, which was assessed using the capital productivity indicator (the ratio of revenue to the residual value of fixed assets). Considering the composition of the initial industry data, econometric models based on panel data were chosen as the tool for processing it. The modeling results established the presence of a positive and almost all-encompassing economies of scale in the pharmaceutical industry. This finding, firstly, indicates the non-economic nature of the low investment activity in the sector and, secondly, favorably characterizes the industry for investors as an "untapped field". The hypothesis of a revenue ceiling for enterprises, exceeding which would indicate a decrease in production efficiency, was not confirmed, emphasizing the almost unlimited commercial potential in the pharmaceutical industry. The methodology for assessing the industry economies of scale has the potential for application to aggregated groups of pharmaceuticals, which could make it practically significant for analytical support in making specific investment decisions.

Keywords

economies of scale; pharmaceutical industry; investment; productivity; SPARK

JEL classification

References

1. Balatsky, E.V., Ekimova, N.A. (2024). Identification of the scale effect in regional-industry production complexes of Russia: theoretical foundations and econometric estimates. Journal of Applied Economic Research, Vol. 23, No. 2, 394–421. (In Russ.). https://doi.org/10.15826/vestnik.2024.23.2.016

         2. Peretto, P., Smulders, S. (2002). Technological distance, growth and scale effects. The Economic Journal, Vol. 112, Issue 481, 603–624. https://doi.org/10.1111/1468-0297.00732

         3. Jones, C.I. (1999). Growth: with or without scale effects? American Economic Review, Vol. 89, No. 2, 139–144. https://doi.org/10.1257/aer.89.2.139

         4. Papageorgiou, C. (2002). On scale effects: further evidence. Applied Economics Letters, Vol. 9, Issue 4, 245–249. https://doi.org/10.1080/13504850110060367

         5. Bond-Smith, S. (2019). The decades-long dispute over scale effects in the theory of economic growth. Journal of Economic Surveys, Vol. 33, Issue 5, 1359–1388. https://doi.org/10.1111/joes.12329

         6. Bond-Smith, S. (2024). Combining agglomeration economies and endogenous growth without scale effects. Spatial Economic Analysis, Vol. 19, Issue 3, 287–308. https://doi.org/10.1080/17421772.2023.2280106

         7. Quo, B., Wang, Q.Z., Shou, Y.Y. (2004). Firm size, R&D, and performance: an empirical analysis on software industry in China. 2004 IEEE International Engineering Management Conference, Vol. 2, 613–616. https://doi.org/10.1109/IEMC.2004.1407451

         8. Xie, B.C., Ni, K.-K., O'Neill, E., Li, H.-Z.. (2021). The scale effect in China's power grid sector from the perspective of malmquist total factor productivity analysis. Utilities Policy, Vol. 69, 101187. https://doi.org/10.1016/j.jup.2021.101187

         9. Yeo, Y., Park, C. (2023). Does firm size matter? Decomposing Korean firms' productivity growth based on a stochastic frontier approach and its policy implications. Asian Journal of Technology Innovation, Vol. 31, Issue 2, 284–308. https://doi.org/10.1080/19761597.2022.2049975

         10. Ugur, M., Trushin, E., Solomon, E. (2016). Inverted-U relationship between R&D intensity and survival: Evidence on scale and complementarity effects in UK data. Research Policy, Vol. 45, Issue 7, 1474–1492. https://doi.org/10.1016/j.respol.2016.04.007

         11. Fang, X., Paez, N.R., Zeng B. (2021). The nonlinear effects of firm size on innovation: an empirical investigation. Economics of Innovation and New Technology, Vol. 30, Issue 1, 48–65. https://doi.org/10.1080/10438599.2019.1677013

         12. Fu, F., Chen, S., Sun, L. (2021). Revenue and cannibalisation: The effect of interchangeable design confronted remanufacturing processing. Processes, Vol. 9, Issue 3, 497. https://doi.org/10.3390/pr9030497

         13. Chandrasekaran, D., Tellis, G.J., James, G.M. (2022). Leapfrogging, cannibalization, and survival during disruptive technological change: the critical role of rate of disengagement. Journal of Marketing, Vol. 86, Issue 1, 149–166. https://doi.org/10.1177/0022242920967912

         14. Lee, J., Kim, M. (2016). Market-driven technological innovation through acquisitions: The moderating effect of firm size. Journal of Management, Vol. 42, Issue 7, 1934–1963. https://doi.org/10.1177/0149206314535439

         15. Madsen, E.S., Wu, Y. (2016). Low R&D efficiency in large pharmaceutical companies. American Journal of Medical Research, Vol. 3, No. 2, 141–151. https://doi.org/10.22381/AJMR3220167

         16. Tyagi, S., Nauriyal, D.K., Gulati, R. (2018). Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry. Review of Managerial Science, Vol. 12, 167–202. https://doi.org/10.1007/s11846-016-0218-8

         17. Anghel, I., Siminică, M., Cristea, M., Sichigea, M., Noja, G.G. (2018). Intellectual capital and financial performance of bio-tech companies in the pharmaceutical industry. Amfiteatru Economic, Vol. 20, No. 49, 631–646. https://doi.org/10.24818/EA/2018/49/631

         18. Bottazzi, G., Secchi, A. (2006). Gibrat's law and diversification. Industrial and Corporate Change, Vol. 15, Issue 5, 847–875. https://doi.org/10.1093/icc/dtl019

         19. You, T., Chen, X., Holder, M.E. (2010). Efficiency and its determinants in pharmaceutical industries: ownership, R&D and scale economy. Applied Economics, Vol. 42, Issue 17, 2217–2241. https://doi.org/10.1080/00036840701765445

         20. Mahajan, V., Nauriyal, D.K., Singh, S.P. (2014). Technical efficiency analysis of the Indian drug and pharmaceutical industry: A non-parametric approach. Benchmarking: An International Journal, Vol. 21, Issue 5, 734–755. https://doi.org/10.1108/BIJ-10-2012-0070

         21. Toma, P. (2020). Size and productivity: a conditional approach for Italian pharmaceutical sector. Journal of Productivity Analysis, Vol. 54, 1–12. https://doi.org/10.1007/s11123-020-00580-y

         22. Lakdawalla, D.N. (2018). Economics of the pharmaceutical industry. Journal of Economic Literature, Vol. 56, No. 2, 397–449. https://doi.org/10.1257/jel.20161327

         23. Comanor, W.S., Scherer, F.M. (2013). Mergers and innovation in the pharmaceutical industry. Journal of Health Economics, Vol. 32, Issue 1, 106–113. https://doi.org/10.1016/j.jhealeco.2012.09.006

         24. Emamgholipour, S., Agheli, L. (2019). Determining the structure of pharmacytical industry in Iran. International Journal of Pharmaceutical and Healthcare Marketing, Vol. 13, Issue 1, 101–115. https://doi.org/10.1108/IJPHM-06-2017-0030

         25. Sunarmo, S., Pardiansyah, E., Asriyah, A. (2023). Concentration and Competition in the Pharmaceutical Sector in an Era of Challenges. Jurnal Ekonomi Pembangunan, Vol. 21, No. 1, 39–48. https://doi.org/10.29259/jep.v21i1.20779

         26. Ipek, E., Ipek, O. (2018). Market structure of the Turkish pharmaceutical industry. Business and Economics Research Journal, Vol. 9, No. 3, 449–462. https://doi.org/10.20409/berj.2018.116

         27. Mahajan, V. (2019). Structural changes and trade competitiveness in the Indian pharmaceutical industry in product patent regime. International Journal of Pharmaceutical and Healthcare Marketing, Vol. 13, Issue 1, 21–39. https://doi.org/10.1108/IJPHM-12-2016-0066

         28. Golikova, V.V., Kuznetsov, B.V. (2021). Strategies of Russian industrial enterprises’ importing behavior under economic sanctions. Voprosy Ekonomiki, No. 7, 89–106. (In Russ.). https://doi.org/10.32609/0042-8736-2021-7-89-106

         29. Simachev, Yu.V., Yakovlev, A.A., Golikova, V.V., et al. (2023). Russian industrial companies in the conditions of the ‘second wave’ of sanctions restrictions: response strategies. Voprosy Ekonomiki, No. 12, 5–30. (In Russ.). https://doi.org/10.32609/0042-8736-2023-12-5-30

         30. Dolgopiatova, T.G., Fedyunina, A.A., Nazarova, A.G. (2021). Pharmaceutical production in Russia during the pandemic: old problems, new challenges. All-Russian Economic Journal ECO, No. 8, 38–63. (In Russ.). https://doi.org/10.30680/ECO0131-7652-2021-8-38-63

         31. Karlova, N., Morozov, A., Puzanova, E. (2023). Import restrictions restrain export: the results of the survey of enterprises. Bank of Russia. Analytical Note, January. (In Russ.). Available at: https://www.cbr.ru/Content/Document/File/144420/analytic_note_20230130_dip.pdf

         32. Kravchenko, N.A., Yusupova, A.T. (2019). Russian pharmaceutical companies: business models of market leaders. Voprosy Ekonomiki, No. 8, 127–138. (In Russ.). https://doi.org/10.32609/0042-8736-2019-8-127-138

         33. Zemtsov, S.P., Chernov, A.V. (2019). What high-tech companies in Russia grow faster and why. Journal of the New Economic Association, Vol. 41, No. 1, 68–99. (In Russ.). https://doi.org/10.31737/2221-2264-2019-41-1-3

         34. Kolchinskaya, E.E., Limonov, L.E., Yakovleva, P.E. (2019). Expediency of cluster policy in the pharmaceutical industry of Russia: exploratory study. Vestnik of St. Petersburg University. Management, Vol. 18, No. 3, 375–399. (In Russ.). http://doi.org/10.21638/11701/spbu08.2019.303

         35. Aleksandrova, E.A., Ivanova, V.I., Kuznetsova, M.Y. (2019). Clusters and cluster initiatives in the biopharmaceutical industry of Russia: identification, structure, geography. Vestnik of St. Petersburg University. Management, Vol. 18, No. 3, 341–374. (In Russ.). doi.org/10.21638/11701/spbu08.2019.302

Acknowledgements

The study was supported by the state assignment to the Finance University for 2024.

About Authors

Гусев Александр Борисович

Кандидат экономических наук, научный сотрудник Финансового университета при Правительстве Российской Федерации, г. Москва, Россия (109456, г. Москва, 4-й Вешняковский проезд, 4); ORCID https://orcid.org/0000-0001-9063-0601 e-mail: abgusev@fa.ru

Юревич Максим Андреевич

Кандидат экономических наук, научный сотрудник Финансового университета при Правительстве Российской Федерации, г. Москва, Россия (109456, г. Москва, 4-й Вешняковский проезд, 4); ORCID https://orcid.org/0000-0003-2986-4825 e-mail: mayurevich@fa.ru

For citation

Gusev, A.B., Yurevich, M.A. (2024). Economies of Scale in The Russian Pharmaceutical Industry: Empirical Assessments. Journal of Applied Economic Research, Vol. 23, No. 4, 1055-1076. https://doi.org/10.15826/vestnik.2024.23.4.041

Article info

Received July 26, 2024; Revised August 14, 2024; Accepted August 26, 2024.

DOI: https://doi.org/10.15826/vestnik.2024.23.4.041

Download full text article: